SCCPDH (Saccharopine dehydrogenase) antibodies target an enzyme involved in the lysine degradation pathway, specifically catalyzing the conversion of saccharopine to α-ketoglutarate and L-glutamate. This mitochondrial enzyme, encoded by the *SCCPDH* gene (located on human chromosome 15q25.3), plays a role in cellular metabolism and energy homeostasis. Structurally, SCCPDH contains conserved NAD-binding and catalytic domains, critical for its enzymatic activity.
Interest in SCCPDH antibodies stems from its potential implications in disease. Elevated SCCPDH expression has been observed in certain cancers, including hepatocellular carcinoma, colorectal cancer, and prostate cancer, where it may promote cell proliferation or inhibit apoptosis. Antibodies against SCCPDH are thus valuable tools for studying its expression patterns, subcellular localization, and mechanistic roles in tumorigenesis via techniques like Western blotting, immunohistochemistry, or immunofluorescence.
Additionally, SCCPDH has been linked to metabolic disorders and neurodegenerative conditions, though its precise role remains under investigation. Research using SCCPDH antibodies could clarify its involvement in lysine metabolism dysregulation and its crosstalk with signaling pathways like mTOR or AMPK. Such studies may inform therapeutic strategies targeting SCCPDH in precision medicine or biomarker development.